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Abstract
Background: Calcium supplements are widely used among older adults for osteoporosis prevention and treatment.
However, their effect on creatinine levels and kidney function has not been well studied.
Methods: We investigated the effect of calcium supplementation on blood creatinine concentration in a randomized
controlled trial of colorectal adenoma chemoprevention conducted between 2004–2013 at 11 clinical centers in the United
States. Healthy participants (N = 1,675) aged 45–75 with a history of colorectal adenoma were assigned to daily
supplementation with calcium (1200 mg, as carbonate), vitamin D3 (1000 IU), both, or placebo for three or five years.
Changes in blood creatinine and total calcium concentration were measured after one year of treatment and multiple linear
regression was used to estimate effects on creatinine concentrations.
Results: After one year of treatment, blood creatinine was 0.01360.006 mg/dL higher on average among participants
randomized to calcium compared to placebo after adjustment for other determinants of creatinine (P = 0.03). However, the
effect of calcium treatment appeared to be larger among participants who consumed the most alcohol (2–6 drinks/day) or
whose estimated glomerular filtration rate (eGFR) was less than 60 ml/min/1.73 m2 at baseline. The effect of calcium
treatment on creatinine was only partially mediated by a concomitant increase in blood total calcium concentration and
was independent of randomized vitamin D treatment. There did not appear to be further increases in creatinine after the
first year of calcium treatment.
Conclusions: Among healthy adults participating in a randomized clinical trial, daily supplementation with 1200 mg of
elemental calcium caused a small increase in blood creatinine. If confirmed, this finding may have implications for clinical
and public health recommendations for calcium supplementation.
Trial Registration: ClinicalTrials.gov NCT00153816
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Introduction
Calcium supplements are widely recommended and commonly
used in the United States, especially by postmenopausal women
for preventing and treating osteoporosis [1–4]. Extraskeletal health
benefits of calcium have also been proposed, including a reduction
in risk of colorectal neoplasms [5–8]. Although observational
studies originally suggested inverse associations with cardiovascu-
lar disease, recent analyses of clinical trials [9–11] as well as a large
prospective cohort study [12] suggest increased cardiovascular risk
from calcium supplementation. However, another recent analysis
did not find increased cardiovascular risk [13]. Additionally, two
recent studies provide evidence of a reduction in all cause
mortality from calcium supplementation alone [14] or with
vitamin D [15]. Potential adverse renal effects of calcium
supplementation include an increased risk of kidney stones [16]
and renal insufficiency associated with hypercalcemia and
metabolic alkalosis in the calcium-alkali syndrome [17]. Further
research is needed to investigate the extraskeletal effects of
supplemental calcium use.
In a randomized controlled trial of the effects of calcium and/or
vitamin D supplementation on colorectal adenoma recurrence,
changes in blood creatinine concentration were measured as a pre-
specified interim outcome for safety to assess potential renal
effects. We observed that calcium treatment for one year was
associated with a small increase in blood creatinine concentration,
suggesting the possibility of an effect on renal function. In the
current report, we analyze the association of calcium treatment
with changes in blood creatinine among the predominantly male,




This study was registered at ClinicalTrials.gov as
NCT00153816 (www.clinicaltrials.gov) on September 7, 2005,
when the investigators first became aware of the opportunity for
trial registration. The authors confirm that all ongoing and related
trials for this drug/intervention are registered. The following
institutional review boards (IRBs) approved the study prior to its
initiation at that site (date of initial approvals are in parentheses):
Dartmouth College Committee for the Protection of Human
Subjects (8/25/03), University of Southern California IRB (3/17/
04), Kaiser Permanente IRB (5/27/04), Colorado Multiple
Institutional Review Board (7/23/04), Emory University IRB
(4/12/04), Atlanta Veterans Affairs Medical Center (VAMC) IRB
(4/12/04), University of Iowa IRB (6/9/04), University of
Minnesota IRB (6/3/04), Minneapolis VAMC IRB (6/29/04),
Portsmouth Regional Hospital IRB (3/24/04), Concord Hospital
IRB (4/1/04), Maine Medical Center IRB (6/7/04), White River
Junction VAMC IRB (3/4/04), University of North Carolina IRB
(5/24/04), Cleveland Clinic IRB (5/21/04), University of Puerto
Rico IRB (9/25/06), San Juan VAMC IRB (11/7/06), Palmetto
Health IRB (4/13/04), University of Texas/MD Anderson
Cancer Center IRB (4/7/04). All participants provided written
informed consent at enrollment. An independent Safety and Data
Monitoring Committee reviewed the study semiannually.
Study Design
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1. The Vitamin D/Calcium Polyp Prevention Study
was a multicenter, placebo-controlled, double-blind, randomized
clinical trial investigating the efficacy of vitamin D, calcium, or
both for preventing sporadic colorectal adenoma recurrence.
Participants were independently randomized to calcium or
vitamin D in a modified two-by-two factorial design. In the ‘‘Full
Factorial’’ component of the study, participants were randomized
with equal probability to four treatment arms: 1000 IU/day
vitamin D3, 1200 mg/day elemental calcium (as carbonate), both
vitamin D3 and calcium, or placebo. In this report, which analyzes
the effect of calcium treatment, we compare the two groups
randomized to calcium (calcium alone or calcium+vitamin D) to
the two ‘‘control’’ groups randomized to no calcium (placebo or
vitamin D alone). In the ‘‘Two Arm’’ component of the study,
women who chose to receive calcium supplementation were
randomized with equal probability to either vitamin D3 plus
calcium or to calcium alone, and are excluded from this report
since they were not randomized to calcium treatment. The
expected duration of the intervention was either 3 or 5 years,
according to the colonoscopy follow-up interval recommended by
the participants’ physicians. Sample size was determined by the
hypothesized treatment effect on the primary outcome of adenoma
recurrence.
Participants were recruited from gastroenterology departments
and practices associated with eleven clinical centers in the United
States; the Project Coordination Center and trial database are
located at The Geisel School of Medicine at Dartmouth.
Eligibility, Enrollment and Randomization
Eligible patients were 45–75 years of age, in good general
health, and had at least one large bowel adenoma removed at a
colonoscopy within four months before enrollment with a
recommended follow-up interval of either 3 or 5 years. Other
inclusion criteria included blood total calcium within the normal
range, creatinine #20% above the upper limit of normal, and 25-
hydroxyvitamin D between 12–90 ng/ml. Exclusion criteria
included a history of a familial colorectal cancer syndromes,
invasive large bowel cancer, malabsorption syndromes, and
indications or contraindications to the study agents (e.g., kidney
stones, granulomatous diseases, hyperparathyroidism, hypercalce-
mia, osteoporosis, osteomalacia, or use of interacting drugs).
Participant recruitment began on 5/15/04 and enrollment
occurred between July 16, 2004 and July 31, 2008. At enrollment,
a detailed questionnaire was administered to collect demographic,
medical and lifestyle data. Race and Hispanic ethnicity were self-
reported. Current height and weight were documented, blood was
collected, and participants completed a Block Brief 2000 Food
Frequency Questionnaire (NutritionQuest, Berkeley, CA). Partic-
ipants were counseled to avoid additional supplementation with
calcium or vitamin D during the study and to reduce their dietary
consumption of calcium if it exceeded 1200 mg/day. Study
multivitamins, formulated without any calcium or vitamin D, were
provided to participants if desired. At enrollment, participants
began a blinded placebo run-in period (56–84 days) to assess
adherence to study procedures before randomization; participants
who took ,80% of their study pills were not randomized. A web-
based program was used to randomize participants in blocks with
computer-generated random numbers; stratification factors in-
cluded full factorial participation, clinical center, sex, and
colonoscopic follow-up interval (3 or 5 years). Identical appearing
study pills contained calcium (600 mg elemental calcium as
carbonate), vitamin D3 (500 IU), both agents, or placebo with
instructions to take one tablet twice daily with food. Participants,
health care providers and investigators were blinded to treatment
assignments.
Calcium Supplementation and Creatinine Concentration
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Follow-up
Participants were interviewed every six months by telephone
regarding adherence to study treatment; use of medications and
nutritional supplements; symptoms, illnesses, medical procedures
and hospitalizations; and dietary intake of calcium and vitamin D.
As pre-specified in the protocol, interim visits were scheduled to
measure blood total calcium, creatinine, and 25-hydroxyvitamin D
one year after randomization, and three years after randomization
for participants with a 5-year follow-up. Participants were
removed from treatment if their calcium was above the normal
range, if their creatinine was .20% above the upper limit of
normal, or if their 25-hydroxyvitamin D was ,10 or.100 ng/ml.
In addition, 25-hydroxyvitamin D was measured at ‘‘end-of-
treatment visits’’ scheduled shortly before the participants’ follow-
up colonoscopies. Creatinine was measured at this time as well for
participants who elected to take part in a ‘‘kidney sub-study’’ of the
renal effects of vitamin D, which was active between September
2010 and April 2012. Additionally, in October 2011 the Safety
and Data Monitoring Committee unblinded the study investiga-
tors to the observed association of calcium treatment with elevated
blood creatinine levels. As a result, the protocol was modified to
include creatinine and calcium measurements annually, to remove
participants from randomized calcium treatment if their creatinine
was above the upper limit of normal or if there was an increase of
$0.3 mg/dL from baseline, and to retrospectively measure
creatinine and calcium on stored specimens from ‘‘end-of-
treatment visits’’ that were completed previously without creati-
nine measurements (at Quest Diagnostics, Denver, CO). Fasting
prior to study blood draws was recommended but not required.
Participant follow-up in the treatment phase of the study ended on
August 31, 2013 and the main results are currently being analyzed.
Laboratory Measurements
Measurements of creatinine and calcium were performed on
fresh serum or plasma samples according to standard procedures
at laboratories associated with the eleven participating clinical
centers. Local laboratory reference ranges were used to identify
out-of-range values. Three clinical centers changed laboratories
during the study. Additionally, measurements of creatinine and
calcium on frozen serum samples collected at ‘‘end-of-treatment
visits’’ completed prior to October 2011 were performed at Quest
Diagnostics (Denver, CO): creatinine was measured using a kinetic
modified Jaffe method (Beckman Coulter Inc., Brea, CA) and total
calcium was measured using an Arsenazo assay (Beckman Coulter
Inc.). All 25-hydroxyvitamin D measurements were performed on
frozen serum samples at the University of California (Los Angeles)
at the Nutrition Research Center Laboratory using a radioimmu-
noassay kit from Immunodiagnostic Systems (IDS, Fountain Hills,
AZ).
Statistical Analyses
Study sample size was based on power calculations for the
primary outcome of adenoma recurrence. T-tests were used to
compare blood creatinine and total calcium concentrations
between treatment groups. A chi-square test was used to compare
the number of participants by treatment group with elevated (out-
of-range) creatinine concentrations or with increases of $0.3 mg/
dL between baseline and year one. Estimated glomerular filtration
rate (eGFR) was calculated using the CKD-EPI equation [18].
Multiple linear regression was used to estimate the effect of
calcium treatment on untransformed year one creatinine concen-
tration or eGFR, adjusting for the baseline level of the respective
outcomes. To generate parsimonious models, race, Hispanic
ethnicity and randomized vitamin D treatment assignment were
forced into the model and other participant characteristics were
chosen for inclusion by backward elimination using the Akaike
Information criterion. Sensitively analyses were conducted to test
the robustness of the results among non-Hispanic whites only,
optimally compliant participants, or participants with a year one
creatinine measurement performed in the same laboratory as their
baseline measurement. In exploratory analyses, effect modification
was examined using Wald tests for interactions between calcium
treatment and other covariates. Due to the large number of
participants missing data on baseline dietary calcium intake (8%),
this variable was excluded from sub-group analyses on the small
number of participants with baseline eGFR,60 ml/min/1.73 m2.
Analyses were conducted according to the intent-to-treat principle,
except as indicated. All statistical tests were two-sided and
considered significant at a value of P,0.05. Statistical analyses
were performed using SAS (version 9.3, Cary, NC).
Results
A total of 1,675 participants were randomized in the Full
Factorial component of the study (Figure 1). Baseline demograph-
ic, lifestyle and other relevant characteristics were similar between
participants in the control or calcium treatment groups (Table 1).
The mean age at enrollment was approximately 58 years, 85% of
participants were male and 85% were Caucasian. Baseline blood
creatinine, total calcium, and 25-hydroxyvitamin D concentrations
were also similar among participants in the control or calcium
treatment groups. A total of 28 participants (1.7%) had an elevated
creatinine within 20% above the lab normal range and 66 (3.9%)
had an eGFR less than 60 ml/min/1.73 m2, a level that, if
persistent, commonly defines chronic kidney disease [18].
Numbers of and reasons for unobtainable blood draws at years
one, three and five were similar between the treatment arms
(Figure 1). Overall, 97.1% of participants (N = 1,627) had a year
one blood draw (Figure 1), which was collected 14.761.4 months
(mean 6 SD) from the baseline blood draw. In the period between
the baseline and year one blood draw, 81.6% of participants
(N = 1,367) were ‘‘optimally compliant’’, defined as taking at least
80% of their study pills, having no gaps in pill taking greater than
7 consecutive days, and taking no personal calcium supplements.
At year one, randomized calcium treatment was associated with
a slightly larger increase in blood creatinine concentration:
0.03860.004 versus 0.02160.004 mg/dL (mean 6 SE)
(P = 0.01) (Table 2). Among participants with a normal creatinine
at baseline, more in the calcium treatment group developed
creatinine concentrations above the normal laboratory reference
range at year one (27 participants in the calcium group and 13 in
the control group, P = 0.02). In addition, more subjects in the
calcium treatment group experienced creatinine increases of at
least 0.3 mg/dL at year one (41 in the calcium group and 26 in the
control group, P = 0.06). As expected, calcium treatment was also
associated with modestly increased blood total calcium concen-
tration (Table 2). In exploratory analyses, in the intervals between
years one and three and between years three and five, there did
not appear to be further increases in blood creatinine or calcium
concentrations due to calcium treatment in analyses including all
participants (Table 2) or in analyses restricted to participants with
blood measurements performed in the same lab as at the prior
time point (Table S1).
Next, we examined the effect of calcium supplementation on year
one creatinine concentration adjusted for baseline creatinine and
other potential determinants of renal function (Table 3). Overall,
the regression model explained 60% of the variance in year one
creatinine (r2 = 0.596). After controlling for characteristics listed in
Calcium Supplementation and Creatinine Concentration
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Table 3, year one creatinine values were on average
0.01360.006 mg/dL (mean 6 SE) higher in the calcium treatment
group than the control group (P = 0.03). In sensitivity analyses,
almost identical results were seen when the analysis was restricted to
optimally compliant participants (0.01360.007 mg/dL, P = 0.05),
to non-Hispanic whites only (0.01360.007 mg/dL, P = 0.06), or to
participants with year one creatinine measurements performed in
the same laboratory as their baseline measurement
(0.01560.006 mg/dL, P = 0.02).
To determine whether the concomitant increase in blood
calcium mediated the effect of calcium supplementation on
creatinine concentration (an increase of 0.01360.006 mg/dL,
mean 6 SE), year one blood calcium concentration was added to
the regression model. For every 1 mg/dL increase in year one
calcium concentration there was an increase of 0.03960.008 mg/
dL (mean 6 SE) in year one creatinine (P,0.0001) and the
coefficient for calcium treatment decreased by about 23% to
0.01060.006 mg/dL (mean 6 SE) (P = 0.11).
Notably, randomized vitamin D treatment did not effect year
one creatinine concentration (Table 3) or modify the effect of
calcium treatment on year one creatinine concentration (Pinterac-
tion = 0.54). It also did not statistically significantly effect blood
calcium concentration at year one, although it was associated with
a net increase in 25-hydroxyvitamin D concentration of 6.7 ng/ml
(P,0.001).
In exploratory analyses, there was suggestive evidence from
subgroup analyses that two factors modified the effect of calcium
supplementation. First, the effect of calcium appeared to be more
pronounced among participants (N = 62) with baseline eGFR ,
60 ml/min/1.73 m2: at year one creatinine was on average
0.1060.05 mg/dL higher (mean 6 SE) (P = 0.06, Pinterac-
tion = 0.01) and the adjusted year one eGFR was on average
4.962.7 ml/min/1.73 m2 lower (mean 6 SE) (P = 0.07, Pinterac-
tion = 0.10). Due to the high rate of missing data on baseline dietary
calcium intake, it was excluded from this sub-group analysis;
however, its inclusion did not change the results. Second, greater
Figure 1. Vitamin D/Calcium Polyp Prevention Study Participant Flow Diagram.
doi:10.1371/journal.pone.0108094.g001
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baseline alcohol consumption appeared to be associated with a
larger effect of calcium treatment, although the interaction was not
statistically significant. Among participants in the highest category
of baseline alcohol consumption (2 to 6 drinks per day, N = 239),
year one creatinine was on average 0.03460.016 mg/dL (mean 6
SE) higher among participants randomized to calcium treatment
(P = 0.04, Pinteratcion = 0.07 for alcohol consumption modeled as
continuous variable).
Discussion
Calcium supplementation (1200 mg/day of elemental calcium,
as calcium carbonate) led to a very modest increase in blood
creatinine concentration in a population of generally healthy 45–
75 year old adults, predominantly white (85%) and male (85%),
who were participating in a randomized clinical trial. After one
year, creatinine concentration was 0.013 mg/dL higher on
average among participants in the calcium treatment group
compared to the control group after adjusting for other
Table 1. Baseline Characteristics of Participants in the Full Factorial Component of the Vitamin D/Calcium Polyp Prevention Study,
by Calcium Treatment Group (N = 1,675).
Characteristic Control1 (N = 835) Calcium2 (N = 840)
Sex (male) 713 (85.4) 710 (84.5)
Age (years) 58.367.0 58.766.9
Race:
Caucasian 721 (86.4) 704 (83.8)
African American 52 (6.2) 79 (9.4)
Asian/Pacific Islander 22 (2.6) 16 (1.9)
Other/Unknown 40 (4.8) 41 (4.9)
Hispanic Ethnicity 43 (5.2) 49 (5.9)
Body Mass Index [weight (kg)/height(m2)] 29.1 (4.7) 29.2 (5.1)
Alcohol Intake (drinks/day):
None 258 (31.1) 255 (30.6)
0.1–1.9 441 (53.1) 462 (55.4)
2–6 131 (15.8) 117 (14.0)
Smoking status:
Never 404 (48.4) 416 (49.5)
Former 357 (42.8) 343 (40.8)
Current 74 (8.9) 81 (9.6)
Physical Activity: Total MET minutes per week 319763030 319662996
Taking multivitamin 432 (51.7) 442 (52.7)
Taking calcium supplement3 65 (7.8) 65 (7.8)
Dietary calcium intake (mg/day) 6586300 6856316
Dietary vitamin D intake (IU/day) 135699 138694
Blood creatinine (mg/dL) 0.9760.16 0.9760.17
Blood creatinine above lab normal range 13 (1.6) 15 (1.8)
eGFR4 ,60 ml/min/1.73 m2 30 (3.6) 36 (4.3)
Blood total calcium (mg/dL) 9.3560.38 9.3460.39
Serum 25-hydroxyvitamin D (ng/ml) 24.668.1 24.668.6
Diuretic use5 144 (17.3) 141 (16.8)
Aspirin use daily 308 (36.9) 300 (35.7)
Non-aspirin NSAID use daily 60 (7.2) 59 (7.0)
Diabetes6 66 (7.9) 85 (10.1)
Data are means 6 SD or number of participants (% of total).
1Includes placebo and vitamin D treatment arms.
2Includes calcium and calcium plus vitamin D treatment arms.
3Taking a calcium supplement separate from a multivitamin.
4Estimated glomerular filtration rate (eGFR) calculated using the CKD-EPI equation [18].
5Includes use of loop, thiazide, and K+-sparing diuretics.
6Participant self-report of diabetes diagnosis or use of medication(s) for diabetes.
Number of participants with missing data: Hispanic ethnicity 3 (1 placebo, 2 calcium); BMI 1 (placebo); alcohol 11 (5 placebo, 6 calcium); taking multivitamin 2 (calcium);
taking calcium supplement 3 (1 placebo, 2 calcium); dietary calcium and vitamin D 129 (64 placebo, 65 calcium); diabetes 1 (placebo).
doi:10.1371/journal.pone.0108094.t001
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determinants of creatinine concentration. However, in exploratory
analyses, the effect of calcium supplementation appeared to be
more pronounced among participants with baseline eGFR ,
60 ml/min/1.73 m2 or among those consuming the most alcohol
(2–6 drinks/day). There was no evidence that randomized vitamin
D treatment independently affected creatinine or modified the
effect of calcium supplementation. In addition, in exploratory
analyses, the effect appeared to be sustained but not progressive
beyond the first year of calcium supplementation.
Although numerous studies have investigated randomized
calcium supplementation for osteoporosis prevention or treatment
[19–29], and/or cancer prevention [5,28,30–32], we could only
find two that reported the effect of calcium supplementation on
blood creatinine. In one [33], 438 participants aged 60 years or
older were randomized to placebo or 600 IU 25-hydroxyvitamin
D or 750 mg elemental calcium for 4 years. The change in serum
creatinine was not significantly different between the three
treatment groups. However, in a study of 295 women aged 46–
55 years randomized to either 1000 or 2000 mg of elemental
calcium daily or no supplementation for 2 years [34], there was a
small but statistically significant increase in serum creatinine in the
calcium supplementation groups, in agreement with our findings.
The mechanism by which calcium supplementation increases
blood creatinine is unknown, but could be due to an effect on renal
function. Some of the effect could be due to the very modest
increase in blood calcium due to calcium supplementation,
possibly through a hemodynamic mechanism. Our statistical
analyses suggest that the increase in blood calcium concentration
explained only about 23% of the increase in creatinine concen-
tration due to calcium supplementation at year one. Other
potential mechanisms include mild vasoconstriction due to
increased calciuria or induction of natriuresis by calcium [35],
which could cause mild dehydration, or possibly increased
calcification of the glomeruli. Notably, it has been suggested that
glomerulosclerosis and atherosclerosis share common mechanisms
[36] and increased vascular calcification has been suggested as a
possible mechanism for an increase in cardiovascular events with
calcium supplementation [11]. Alternatively, calcium supplemen-
tation may increase the creatinine load or change renal handling
of creatinine without a direct effect on kidney function (i.e.,
without reducing glomerular filtration). For example, treatment
with an active vitamin D analogue increased creatinine production
and serum creatinine without modifying the glomerular filtration
rate [37]. Further research investigating other biomarkers of renal
function (e.g, cystatin C) could help to distinguish between these
possibilities.
The clinical relevance of the increase in creatinine associated
with one year of calcium supplementation in our study is
uncertain, but our exploratory analyses suggest that it may be
larger and therefore more important in individuals with pre-
existing renal impairment or alcohol consumption. Notably, rapid
declines in kidney function of the magnitude reported here for the
participants with pre-existing renal impairment (5 ml/min/
1.73 m2) have been associated with increased cardiovascular risk
and mortality [38,39]. In addition, even among participants with
normal creatinine concentration at baseline in our study,
significantly more developed creatinine concentrations above the
normal reference range in the calcium group compared to the
control group. However, some common medications that increase
creatinine are nonetheless associated with renal protection [40]. In
general, more attention to potential adverse effects of dietary
supplements is warranted [41,42]. Although some evidence
supports the use of calcium supplements for the prevention and
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(without vitamin D) is not very strong. Potential adverse effects
include kidney stones [16,45] and the emerging evidence on
cardiovascular risk [11,46]. Another consideration is whether
supplemental calcium has different effects than calcium that is
obtained from dietary sources and/or whether the effects may
differ according to the timing of intake relative to ingestion of food
[12,47–50]. Finally, calcium-based phosphate binders are routine-
ly used to lower phosphorus levels in patients with chronic kidney
disease prior to end stage renal disease. While the effect of these
binders on kidney progression has not been evaluated systemat-
ically, in an observational study in Australia, phosphate binders
(type not specified) were associated with faster CDK progression
[51] and in a small randomized clinical trial comparing 3 different
clinically available phosphate binders, only a participant in the
calcium-based binder group experienced an episode of acute
kidney injury [52]. Based on our data and these other suggestive
analyses, studies are needed to evaluate the effects of calcium-
based phosphate binders on kidney disease progression.
The strengths of this study include the well-characterized
population, with uniform and detailed collection of participant
characteristics at the time of enrollment. The randomized
exposure to calcium supplementation minimizes concerns about
confounding suggesting that the differences we observed could be
due to a causal effect. Participant compliance with study
procedures was excellent, including scheduled blood draws, pill
taking and avoidance of outside use of the study agents. Results are
generalizable to a putatively healthy outpatient population
receiving preventative health care, although the participants
analyzed were predominantly male, as 70% of women female
participants chose to receive calcium supplementation.
There are also several limitations. Blood creatinine concentra-
tion was used as a surrogate for renal function and we do not have
data on other markers of renal function nor did we directly
measure the glomerular filtration rate. In addition, creatinine
measurements were performed in many different laboratories and
some laboratories may have changed assays over the course of the
trial. Nonetheless, the additional variability introduced should not
differentially impact the randomized treatment groups and would
likely have biased our results towards the null. Also, given the small
effect size, we had limited power to detect effect modification in
the sub-group analyses. Finally, we did not measure blood ionized
calcium concentrations, and had to rely on total calcium.
In summary, results from a randomized placebo-controlled trial
indicate that supplementation with 1200 mg of elemental calcium
daily is associated with a small increase in blood creatinine in
healthy adults. This finding is important to investigate further,
considering that a large proportion of older individuals take
calcium supplements [2] and chronic kidney disease is a common
and growing public health threat in that population [53,54].
Table 3. Adjusted Effect Measures for the Association of Participant Characteristics with Year One Blood Creatinine Concentration
Using Multiple Linear Regression (N = 1,500).
Characteristics Change3 (SE) P
Baseline creatinine1 (per mg/dL) 0.747 (0.020) ,0.001
Age1 (per year) 0.0011 (0.0005) 0.01
Female sex 20.072 (0.010) ,0.001
Race: 0.85
Caucasian reference
African American 0.001 (0.013)
Asian/Pacific Islander 20.016 (0.022)
Other/Unknown 20.010 (0.019)









Dietary Calcium Intake1 (per 100 mg) 20.002 (0.001) 0.02
Diuretic Use2 0.015 (0.008) 0.05
Vitamin D Treatment Group 0.005 (0.006) 0.42
Calcium Treatment Group 0.013 (0.006) 0.03
Of N = 1,627 participants with year one creatinine available for analysis, 127 are not included due to missing data (see Table 1). CI, confidence interval.
Characteristics chosen for inclusion by backward elimination using the Akaike Information criterion for model selection, with race, Hispanic ethnicity and randomized
vitamin D treatment group forced into the model; characteristics are from baseline, except diuretic use (see 2); results for study centers not shown.
1Characteristics are modeled as continuous variables with units as shown.
2Diuretic use between baseline and year one blood draws.
3Change in creatinine (mg/dL) associated with the exposure (mean, coefficient).
doi:10.1371/journal.pone.0108094.t003
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